Home » Stocks » Immuron

Immuron Limited (IMRN)

Stock Price: $7.21 USD -0.14 (-1.90%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 32.11M
Revenue (ttm) 1.68M
Net Income (ttm) -4.63M
Shares Out 4.45M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $7.21
Previous Close $7.35
Change ($) -0.14
Change (%) -1.90%
Day's Open 7.33
Day's Range 6.92 - 7.40
Day's Volume 43,791
52-Week Range 1.55 - 28.99

More Stats

Market Cap 32.11M
Enterprise Value 28.50M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 4.45M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.68
FCF / Share -0.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6,398
Short Ratio 0.10
Short % of Float n/a
Beta 2.50
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 19.10
PB Ratio 10.16
Revenue 1.68M
Operating Income -3.64M
Net Income -4.63M
Free Cash Flow -1.27M
Net Cash 3.61M
Net Cash / Share 0.81
Gross Margin 72.05%
Operating Margin -216.33%
Profit Margin -194.00%
FCF Margin -75.42%
ROA -24.70%
ROE -45.05%
ROIC -155.50%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $7.21
Target: 194.85
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial numbers in millions AUD.

Financial Overview

Revenue Growth29.55%31.99%39.47%-0.13%2.17%-
Gross Profit1.721.421.060.430.490.51
Operating Income-5.16-4.84-8.33-8.27-4.28-2.84
Net Income-4.63-3.01-6.80-7.07-2.69-2.50
Shares Outstanding143130135135--
Earnings Per Share-1.28-0.90-2.56-3.70-1.44-2.38
Operating Cash Flow-1.80-3.50-6.94-5.16-3.02-2.65
Capital Expenditures--0.01-0.01---0.02
Free Cash Flow-1.80-3.51-6.95-5.16-3.02-2.67
Cash & Equivalents5.124.733.992.293.12-
Total Debt--0.371.90--
Net Cash / Debt5.124.733.630.393.12-
Book Value7.358.446.574.944.81-
Numbers in millions AUD, except per-share numbers.

Company Profile

Company Details

Full Name Immuron Limited
CEO Jerry Kanellos

Stock Information

Ticker Symbol IMRN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMRN


Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Blackburn North, Australia.